Business|May 26, 2026|2 min read

Eli Lilly to buy three small vaccine developers

Eli Lilly announced plans to acquire three early- and mid-stage vaccine developers—Curevo, LimmaTech Biologics, and Vaccine Company—in deals worth up to nearly $4 billion combined. The acquisitions align with Lilly's strategy to prevent severe health problems caused by pathogens that can result in long-term health issues.

#eli-lilly#vaccine-developers#pharmaceutical-acquisitions#curevo#limmatech-biologics#vaccine-company#m-and-a#biotech#glp-1#pharma

STAT

Contributor

Eli Lilly to buy three small vaccine developers

The companies are working on shots against pathogens that can cause long-term health issues

Eli Lilly announced on Tuesday its intentions to acquire three early- and mid-stage vaccine developers, marking a significant advance for the vaccine sector.

The total potential cost of these acquisitions could reach nearly $4 billion. This move reflects Lilly’s ongoing strategy to leverage its substantial cash reserves, bolstered by its successful GLP-1 business. In recent months, the company has also taken steps to acquire firms focused on various health conditions, including cancer, autoimmune diseases, and sleep disorders, each at a valuation below $10 billion.

The three companies included in these transactions are Curevo, LimmaTech Biologics, and Vaccine Company.

Share this story

Spotify aims for 1 billion users and 20% operating margins by 2030. Here's how it plans to get there

At its first Investor Day since 2022, Spotify outlined ambitious growth targets including 1 billion active users and $100 billion in annual revenue by 2030, driven by improved monetization across subscriptions, advertising, and new product layers like AI-powered features.